Yann Tan - Atreca Chief Technologist
| BCELDelisted Stock | USD 1.04 0.02 1.89% |
Insider
Yann Tan is Chief Technologist of Atreca Inc
| Phone | 650 595 2595 |
| Web | https://www.atreca.com |
Atreca Management Efficiency
The company has return on total asset (ROA) of (0.512) % which means that it has lost $0.512 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.827) %, meaning that it created substantial loss on money invested by shareholders. Atreca's management efficiency ratios could be used to measure how well Atreca manages its routine affairs as well as how well it operates its assets and liabilities.Atreca Inc currently holds 63.88 M in liabilities with Debt to Equity (D/E) ratio of 0.57, which is about average as compared to similar companies. Atreca Inc has a current ratio of 7.98, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Atreca until it has trouble settling it off, either with new capital or with free cash flow. So, Atreca's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Atreca Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Atreca to invest in growth at high rates of return. When we think about Atreca's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Michael Fischbach | Revolution Medicines | 43 | |
| Jack Anders | Revolution Medicines | 47 | |
| Peter Heutink | Alector | N/A | |
| Walter Reiher | Revolution Medicines | N/A | |
| David Epstein | Black Diamond Therapeutics | 65 | |
| Elizabeth Buck | Black Diamond Therapeutics | 49 | |
| Sergey MD | Black Diamond Therapeutics | 55 | |
| Adrian Krainer | Stoke Therapeutics | 65 | |
| Dawn Kalmar | Stoke Therapeutics | 46 | |
| David Pompliano | Revolution Medicines | N/A | |
| Desiree DDS | Passage Bio | N/A | |
| Joan Wood | Stoke Therapeutics | N/A | |
| JD Esq | Black Diamond Therapeutics | 59 | |
| Margaret JD | Revolution Medicines | 61 | |
| Michelle Corral | Alector | N/A | |
| David MD | Passage Bio | N/A | |
| MSc MBA | Passage Bio | 55 | |
| Path FRCP | Revolution Medicines | 61 | |
| Eric Rojas | Stoke Therapeutics | N/A | |
| Simona King | Passage Bio | 52 | |
| Clare MBA | Alector | N/A | |
Management Performance
| Return On Equity | -1.83 | |||
| Return On Asset | -0.51 |
Atreca Inc Leadership Team
Elected by the shareholders, the Atreca's board of directors comprises two types of representatives: Atreca inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Atreca. The board's role is to monitor Atreca's management team and ensure that shareholders' interests are well served. Atreca's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Atreca's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yann Tan, Chief Technologist | ||
| Herbert Cross, Chief Officer | ||
| Philippe MD, Chief Officer | ||
| Stephen Gould, Chief Officer | ||
| Rick Ruiz, Principal Officer | ||
| Tito Serafini, Founder Director | ||
| John MBA, CEO and Presidentident | ||
| John Orwin, CEO Pres | ||
| Courtney JD, General Secretary | ||
| Roger Ruiz, Vice Finance |
Atreca Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Atreca a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.83 | |||
| Return On Asset | -0.51 | |||
| Current Valuation | (17.08 M) | |||
| Shares Outstanding | 38.41 M | |||
| Shares Owned By Insiders | 2.73 % | |||
| Shares Owned By Institutions | 24.54 % | |||
| Number Of Shares Shorted | 272.73 K | |||
| Price To Earning | (3.53) X | |||
| Price To Book | 0.28 X | |||
| EBITDA | (76.42 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Consideration for investing in Atreca Pink Sheet
If you are still planning to invest in Atreca Inc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Atreca's history and understand the potential risks before investing.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |